Compare BridgeBio Pharma Inc (BBIO) vs JPMorgan Diversified Return International Eqty ETF (JPIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs JPMorgan Diversified Return International Eqty ETF — how do they compare? BridgeBio Pharma Inc trades at $84.5 (market cap $16.36B), while JPMorgan Diversified Return International Eqty ETF trades at $76.97. The key difference: JPMorgan Diversified Return International Eqty ETF is trading nearer its 52-week high, BridgeBio Pharma Inc nearer its low. Which is the better fit depends on your goals.
| BBIO | JPIN | |
|---|---|---|
Market Cap | $16.36B | — |
Sector | Health | — |
52-Week High | $90.17 | $77.00 |
52-Week Low | $47.29 | $64.96 |
Enterprise Value | $18.14B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.57, down slightly by 0.12% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q2 2026 revenue growth driven by Attruby sales, though it missed EPS estimates. With a high P/S ratio of 22.77 and negative profitability metrics, the stock is priced for future growth, supported by strong analyst buy ratings and a $104.56 consensus price target.
The outlook hinges on successful product launches and regulatory approvals, with three potential launches expected within 12 months offering significant upside. Key risks include persistent cash burn, high debt, and execution challenges in bringing new treatments to market, which could pressure the stock if milestones are missed.
JPIN, the JPMorgan Diversified Return International Equity ETF, trades at $76.97, up 0.8% on the day, with a bullish technical signal driven by moving averages. The ETF provides broad exposure to foreign large-cap value stocks. Key technical indicators show overbought conditions with RSI levels above 74, while the ADX indicates a strong trend. A dividend of $0.91 per share is scheduled for payment in June 2026.
The outlook for JPIN is supported by its smart beta strategy targeting international value equities, though overbought technicals suggest near-term consolidation risk. Investment appeal lies in diversified global exposure, but risks include currency fluctuations and international market volatility. The absence of current fundamental data limits valuation assessment, requiring reliance on technical and sentiment indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About JPMorgan Diversified Return International Eqty ETF
The fund will invest at least 80% of its assets in securities included in the underlying index. The underlying index is comprised of equity securities across developed global markets (excluding North America) selected to represent a diversified set of factor characteristics.
Read more on JPIN →
